Sign in
TerminatedPhase 2

Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium Abscessus

Key facts

Who runs it
Papworth Hospital NHS Foundation Trust
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 2
People taking part
6 people enrolled
Started
1 Nov 2021
Ended
23 Apr 2024
Type of study
Interventional
Treatments tested
  • RESP301
Record updated
10 May 2024
Why it stopped
TSC recommended early termination due to lack of futility of the trial.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Adult patients of ≥18 years at time of informed consent
  • Patients with a clinical diagnosis of CF and confirmed by genetic testing
  • Diagnosis of treatment naïve or treatment refractory M. abscessus-PD
  • Signed informed consent documentation (indicating an understanding of the purpose and a willingness to meet the requirements for participation in the study)

Who cannot take part

  • Use of phosphodiesterase inhibitors (e.g., sildenafil) within 30 days of proposed first treatment
  • Subjects who have undergone organ transplantation
  • Changes to previous NTM antibiotic regimen within two months of first dose of study treatment (or 4 months for clofazimine)
  • Subject has received investigational treatment as part of another interventional clinical trial within two months of the proposed first day of treatment
  • Evidence of pulmonary hypertension
  • History of frequent low volume or massive haemoptysis
  • Liver disease (i.e. liver cirrhosis, portal hypertension)
  • Use of nitric oxide donor medications such as prilocaine, sodium nitroprusside, and nitroglycerine within 30 days of proposed first treatment
  • FEV1 <40% predicted
  • Methaemoglobin concentration > 2%
  • Pregnancy or lactation (female participants only)
  • Subjects who will not use appropriate forms of contraception for the duration of the study
  • Contraindication or unable to complete lung function testing
  • Contraindication or unable to tolerate nebulised hypertonic saline
  • Required antibiotic treatment for a pulmonary exacerbation within 2 weeks of enrolment to the study
  • Inability to undergo study related activities and / or commitments
  • Any subject who in the opinion of the investigator would not be best served by participating in this clinical trial

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

* To evaluate the change in M. abscessus cfu/g in induced sputum samples from baseline to the end of treatment with RESP301 in patients with cystic fibrosis who have treatment-naïve or treatment-refractory M. abscessus-pulmonary disease * To assess the safety and tolerability of RESP301 during treatment (28 days) and follow up (84 days) in patients with cystic fibrosis who have treatment naïve or treatment refractory M. abscessus-pulmonary disease

The group in the trial

  • InterventionalTreatment being tested

    Single arm trial involving all patients receiving IMP

    Treatment: RESP301

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase II Open Label Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium Abscessus Pulmonary Disease
Record updated
10 May 2024